SEARCH

SEARCH BY CITATION

References

  • 1
    Bartlett JG. Antibiotic-associated diarrhoea. N Engl J Med 2002; 346: 3349.
  • 2
    Bartlett JG, Chang TW, Gurwith M, Gorbach SL, Onderdonk AB. Antibiotic-associated pseudomembranous colitis due to toxin producing clostridia. N Engl J Med 1978; 298: 5314.
  • 3
    Wiström J, Norrby SR, Myhre EB, et al. Frequency of antibiotic-associated diarrhoea in 2462 antibiotic-treated hospitalized patients: a prospective study. J Antimicrob Chemother 2001; 47: 4350.
  • 4
    McFarland LV. Epidemiology, risk factors and treatments for antibiotic-associated diarrhoea. Dig Dis 1998; 16: 292307.
  • 5
    Turck D, Bernet JP, Marx J, et al. Incidence and risk factors of oral antibiotic-associated diarrhoea in an outpatient pediatric population. J Pediatr Gastroenterol Nutr 2003; 37: 226.
  • 6
    Elstner CL, Lindsay AN, Book LS, Matsen JM. Lack of relationship of Clostridium difficile to antibiotic-associated diarrhoea in children. Pediatr Infect Dis 1983; 2: 3646.
  • 7
    Barbut F, Meynard JL, Guiguet M, et al. Clostridium difficile-associated diarrhoea in HIV infected patients: epidemiology and risk factors. J Acquir Immune Defic Syndr 1997; 16: 17681.
  • 8
    McFarland LV, Surawicz CM, Stamm WE. Risk factors for Clostridium difficile carriage and C. difficile-associated diarrhoea in a cohort of hospitalized patients. J Infect Dis 1990; 162: 67884.
  • 9
    Diplock AT, Aggett PJ, Ashwell M, et al. Scientific concepts of functional foods in Europe: consensus document. Br J Nutr 1999; 81 (Suppl. 1): S1S27.
  • 10
    Surawicz CM. Probiotics, antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in humans. Best Pract Res Clin Gastroenterol 2003; 17: 77583.
  • 11
    Kotowska M, Albrecht P, Szajewska H. Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea in children: a randomized double-blind placebo-controlled trial. Aliment Pharmacol Ther 2005; 21: 58390.
  • 12
    D'Souza AL, Rajkumar C, Cooke J, Bulpitt CJ. Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis. Br Med J 2002; 324: 13614.
  • 13
    Cremonini F, di Caro S, Nista EC, et al. Meta-analysis: The effect of probiotic administration on antibiotic-associated diarrhoea. Aliment Pharmacol Ther 2002; 16: 14617.
  • 14
    Robinson KA, Dickersin K. Development of a highly sensitive search strategy for the retreival of reports of controlled trials using PubMed. Int J Epidemiol 2002; 31: 1503.
  • 15
    Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. Br Med J 1997; 315: 62934.
  • 16
    Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF, for the QUOROM Group. Improving the Quality of Reports of Meta-analyses of randomised controlled trials: the QUOROM statement. Lancet 1999; 354: 1896900.
  • 17
    Adam J, Barret A, Barret-Bellet C. Essais cliniques contrôlés en double insu de l'ultra-levure lyophilisée: étude multicentrique par 25 médicins de 388 cas. Gaz Med Fr 1977; 84: 20728.
  • 18
    Surawicz CM, Elmer GW, Speelman P, McFarland LV, Chinn J, van Belle G. Prevention of antibiotic-associated diarrhoea by Saccharomyces boulardii: a prospective study. Gastroenterology 1989; 96: 9818.
  • 19
    Lewis SJ, Potts LF, Barry RE. The lack of therapeutic effect of Saccharomyces boulardii in the prevention of antibiotic-related diarrhoea in elderly patients. J Infect 1998; 36: 1714.
  • 20
    McFarland LV, Surawicz CM, Greenberg RN, et al. Prevention of beta-lactam-associated diarrhoea by Saccharomyces boulardii compared with placebo. Am J Gastroenterol 1995; 90: 43948.
  • 21
    Hotz J. Prevention of antibiotic-associated diarrhoea by Saccharomyces boulardii: a prospective study. Z Gastroenterol 1990; 28: 25960 (German).
  • 22
    Surawicz CM, McFarland LV, Elmer G, Chinn J. Treatment of recurrent Clostridium difficile colitis with vancomycin and Saccharomyces boulardii. Am J Gastroenterol 1989; 84: 12857.
  • 23
    Potts L, Lewis SJ, Barry R. Randomised double blind placebo controlled study of the ability of Saccharomyces boulardii to prevent antibiotic related diarrhoea [abstract]. Gut 1996; 38 (Suppl. 1): A61.
  • 24
    Donat F. Prevention of intestinal side-effects of antibiotics with perenterol. Munch Med Wochenschr 1970; 112: 747 (German).
  • 25
    Elmer GW, McFarland LV. Suppression by Saccharomyces boulardii of toxigenic Clostridium difficile overgrowth after vancomycin treatment in hamsters. Antimicrob Agents Chemother 1987; 31: 12931.
  • 26
    Erdeve O, Tiras U, Dallar Y. The probiotic effect of Saccharomyces boulardii in a pediatric age group. J Trop Pediatr 2004; 50: 2346.
  • 27
    Schellenberg D, Bonington A, Champion CM, Lancaster R, Webb S, Main J. Treatment of Clostridium difficile diarrhoea with brewer's yeast. Lancet 1994; 343: 1712.
  • 28
    Surawicz CM, McFarland LV, Greenberg RN, et al. The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Inf Dis 2000; 31: 10127.
  • 29
    McFarland LV, Surawicz CM, Greenberg RN, et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 1994; 271: 19138. Erratum in: JAMA 1994; 272: 518.
  • 30
    Buts JP, Corthier G, Delmee M. Saccharomyces boulardii for Clostridium difficile-associated enteropathies in infants. J Pediatr Gastroenterol Nutr 1993; 16: 41925.
  • 31
    Schellenberg D, Bonningotn A, Champion CM, Lancaster R, Webb S, Main J. Treatment of Clostridium difficile diarrhoea with brewer's yeast. Lancet 1994; 343: 1712.
  • 32
    Pothoulakis C, Kelly CP, Joshi MA, et al. Saccharomyces boulardii inhibits Clostridium difficile toxin A binding and enterotoxicity in rat ileum. Gastroenterology 1993; 104: 110815.
  • 33
    Wilson KH, Perini I. Role of competition for nutrients in suppression of Clostidium difficile by the colonic microflora. Infect Immun 1988; 56: 26104.
  • 34
    Qamar A, Aboudola A, Warny M, et al. Saccharomyces boulardii stimulates intestinal immunoglobulin A immune response to Clostridium difficile toxin A in mice. Infect Immun 2001; 69: 27625.
  • 35
    Tasteyre A, Barc MC, Karjalainen T, et al. Inhibition of in vitro cell adherence of Clostridium difficile by Saccharomyces boulardii. Microbiol Pathogens 2002; 32: 21925.
  • 36
    Bassetti S, Frei R, Zimmerli W. Fungemia with Saccharomyces cerevisiae after treatment with S. boulardii. Am J Med 1998; 105: 712.
  • 37
    Rijnders BJA, Van Wijngaerden E, Verwaest C, Peetermans WE. Saccharomyces fungemia complicating S. boulardii treatment in a non-immunocompromised host. Intensive Care Med 2000; 26: 825.
  • 38
    Zunic P, Lacotte J, Pegoix M, et al. S. boulardii fungemia. Apropos of a case. Therapie 1991; 46: 4989.
  • 39
    Cassone M, Serra P, Mondello F, et al. Outbreak of Saccharomyces cerevisiae subtype boulardii fungemia in patients neighboring those treated with a probiotic preparation of the organism. J Clin Microbiol 2003; 41: 53403.